Skip to main content

Drug Safety

    RT @Janetbirdope: Filgo reduces PsA markers OP0224. ? Unique to filgo, a JAK1 effect , class effect or part of any effec
    3 years 11 months ago
    Filgo reduces PsA markers OP0224. ? Unique to filgo, a JAK1 effect , class effect or part of any effective PsA Rx or some of the above? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/2O5wsLPNl2
    RT @drdavidliew: To truly address adherence, you need to understand what is impairing it, and tailor an approach to over
    3 years 11 months ago
    To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers. Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes! EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV
    RT @KDAO2011: #EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter g
    3 years 11 months ago
    #EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal. Results: 63% flared who had TNFi w/drawn vs. 5% when TNFi continued @RheumNow https://t.co/SsR1vUGbOe
    Analysis of the UK THIN database shows that delays in receiving followup Denosumab injx results in higher fracture risk
    3 years 11 months ago
    Analysis of the UK THIN database shows that delays in receiving followup Denosumab injx results in higher fracture risk (vertebral & Maj OP Fx). 6144 infusions in 2594 pts, shows risk if delay is >16wks (long delay), but not if 4-16wks #EULAR20 SAT0453 https://t.co/DkJK3dHeRN https://t.co/r7ckpSF6PA
    H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain,
    3 years 11 months ago
    H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain, FACIT, Boolean remission); But UPA has more serious AE (vs ABA) - esp hepatic, OI, SIE, SAE, CPK (but not zoster VTE) #EULAR20 SAT0151 https://t.co/K96lybdg7L https://t.co/vQM2MSCNzD
    RT @jcsam25: Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19
    Several studies wi
    3 years 11 months ago
    Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19 Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups) #EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9
    RT @Janetbirdope: VTE elevated risk is assoc up to 1 yr after high disease activity in RA 1% over 1 yr of active RA will
    3 years 11 months ago
    VTE elevated risk is assoc up to 1 yr after high disease activity in RA 1% over 1 yr of active RA will get VTE OP0034 Data from Swedish popn study implications irrespective for which Rx pt gets? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR20 #eular2020 https://t.co/A7mWoYZI9S
    RT @drdavidliew: JAKi and VTE from @WHO VigiBase @UMCGlobalSafety

    Why the difference between Europe and US?

    There may
    3 years 11 months ago
    JAKi and VTE from @WHO VigiBase @UMCGlobalSafety Why the difference between Europe and US? There may be a class effect here (there may not be), but if we really want real-world answers we need effective systematic real-world data collection OP0237 #EULAR2020 @RheumNow https://t.co/Bh2iLpGdXM
    RT @EBRheum: MAINRITSAN3 RCT, RTX v PLBO in AAV

    28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% v
    3 years 11 months ago
    MAINRITSAN3 RCT, RTX v PLBO in AAV 28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8) 1. Selected grp (all pts from MAINRITSAN2) 2. All pts had GC q3mos - IRL benefit could be bigger? Strong data for RTX >2yrs in AAV PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
    RT @philipcrobinson: Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data f
    3 years 11 months ago
    Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7